Rhythm Pharmaceuticals Inc (RYTM : NASDAQ)
Common Stock
$110.68
USD
+24.24 (28.04%)
Last updated: 2026-11-04
Follow RYTM
RYTM
Rhythm Pharmaceuticals Inc
WealthAwesomePerformance
1 Day
+28.04%
1 Week
+20.34%
1 Month
+19.72%
YTD
+15.50%
Key Statistics
Market Cap
$5.99B
52W High
$122.20
52W Low
$74.50
P/E Ratio
-
50 Day MA
$96.35
200 Day MA
$96.95
Beta
2.13
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/4/2026 | $85.94 | $110.68 | $85.04 | $110.68 | $110.68 | 5,485,800 |
| 11/3/2026 | $84.83 | $89.28 | $81.58 | $86.44 | $86.44 | 7,109,799 |
| 11/2/2026 | $93.13 | $95.35 | $92.40 | $93.44 | $93.44 | 2,003,953 |
| 10/30/2026 | $93.48 | $95.59 | $91.42 | $92.57 | $92.57 | 431,700 |
| 10/29/2026 | $93.00 | $94.16 | $92.52 | $93.07 | $93.07 | 754,837 |
| 10/28/2026 | $91.37 | $92.70 | $91.05 | $91.97 | $91.97 | 525,331 |
| 10/27/2026 | $89.36 | $92.72 | $88.72 | $92.18 | $92.18 | 398,019 |
| 10/26/2026 | $90.07 | $90.81 | $89.00 | $89.47 | $89.47 | 289,447 |
| 10/23/2026 | $90.44 | $90.44 | $88.56 | $89.27 | $89.27 | 536,900 |
| 10/22/2026 | $88.85 | $90.95 | $87.59 | $90.90 | $90.90 | 480,316 |
Analyst Price Targets
Based on 19 analysts covering RYTM · as of Nov 5, 2026
Wall Street analysts forecast RYTM stock price to rise 26.8% over the next 12 months.
Consensus
Strong Buy4.53 / 5.00
Avg. Target
US$140.29
+26.8% Upside
Previously US$140.53 on Oct 26, 2026
Current Price
US$110.68
Last close
Analyst Breakdown (19 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on RYTM's historical volatility
30-Day Vol
80.7%
Annualized
90-Day Vol
56.5%
Annualized
Trend (90d)
-8.1%
Annualized drift
90d Mean
US$107.51
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$109.61 | US$82.98 – US$144.80 |
| 60 trading days | US$108.56 | US$73.23 – US$160.93 |
| 90 trading days | US$107.51 | US$66.38 – US$174.13 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Financials
- Revenue (TTM)
- $239.92M
- EBITDA
- $-199.55M
- Profit Margin
- -85.59%
- ROE (TTM)
- -117.05%
- EPS (Diluted)
- -2.91
- Book Value
- 2.07
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About RYTM.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| INM | InMed Pharmaceuticals Inc | $17.50 | +941.67% |
| OMH | Ohmyhome Limited Ordinary Shares | $15.55 | +432.53% |
| CRIS | Curis Inc | $1.11 | +56.34% |
| PMAX | Powell Max Limited Class A Ordinary Shares | $1.04 | +54.07% |
| RFAIR | RF Acquisition Corp II Right | $0.24 | +50.00% |
| CRCT | Cricut Inc | $8.88 | +48.74% |
| LYEL | Lyell Immunopharma Inc | $15.43 | +43.27% |
| GENVR | Gen Digital Inc. Contingent Value Rights | $4.03 | +42.40% |